Medication Guide App

BioGeneriX and Neose to Host Conference Call to Present GlycoPEG-GCSF Phase I Data

MANNHEIM, Germany & HORSHAM, Pa.--(BUSINESS WIRE)--Nov 1, 2007 - BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that they will host a conference call on Wednesday, November 7, 2007 at 8:00 a.m. (EST) to present data from two Phase I clinical studies of GlycoPEG-GCSF, comprising both ascending- and fixed-dose studies versus Neulasta(R). The call is expected to last approximately 30 minutes and will include prepared remarks by Neose and BioGeneriX with a subsequent question and answer period. A slide presentation of the data will be available via the webcast.

The dial-in number for domestic callers is (800) 896-8445. The dial-in number for international callers is (785) 830-1916. A replay of the call will be available for 7 days beginning approximately three hours after the conclusion of the call. The replay number for domestic callers is (888) 203-1112, using the passcode 1841153. The replay number for international callers is (719) 457-0820, also using the passcode 1841153. The call will also be webcast live through the Company's website via the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-calendar

To listen to the live call, please go to the web site at least fifteen minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call.

About G-CSF and Neutropenia

G-CSF is prescribed to stimulate the production of neutrophils, and is approved for sale in major markets around the world for the treatment of neutropenia associated with myelosuppressive chemotherapy. Worldwide sales in the G-CSF category exceeded $4 billion in 2006. Neutropenia is a severe reduction in the number of neutrophils (mature white blood cells) in the circulating blood, commonly associated with cancer chemotherapy. Patients with neutropenia are at increased risk of developing serious infection. If not treated promptly, neutropenia can be life-threatening.

About BioGeneriX AG

BioGeneriX was founded in June 2000 to develop biopharmaceutical drugs with known modes of action and established drug markets. With its internal resources and a large network of strategic partners and service providers, BioGeneriX develops a high-quality biotech portfolio for marketing and distribution by its parent company and global partners. For more information, visit its website at www.biogenerix.com.

About the ratiopharm Group

ratiopharm is Europe's leading generics producer and in its home country Germany the top selling and most commonly prescribed pharmaceutical brand. The company produces high quality medicines and sells them at low prices. By doing so, it contributes to cost containment in the healthcare sector. With over 700 medicines, available exclusively from pharmacies, it has one of the widest product ranges in the business. ratiopharm sells 472 million pack units every year, meeting the needs of virtually all areas of medicine, from allergies to circulation problems and from gastroenteritis to toothaches. Founded in 1974, ratiopharm is now bringing its business model and experience to international markets. It is already active in 24 countries. In 2006, ratiopharm generated worldwide revenues of 1.7 billion Euros, of which 800 million Euros were from sales in Germany. For more information, visit its website at www.ratiopharm.de.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic kidney disease and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with 2006 aggregate sales in excess of $15 billion. For more information, please visit www.neose.com.

Contact

BioGeneriX AG
Thomas Brennecke, PhD
Director, Business Development
Phone +49 621 875 56 10
or
Neose Technologies, Inc.
A. Brian Davis
Sr. Vice President and Chief Financial Officer
215-315-9000
or
Barbara Krauter
Manager, Corporate Communications
215-315-9004

Posted: November 2007

View comments

Hide
(web5)